Clinical Trials · NCT03363906
A Study of Dulaglutide in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 27
- Start date
- Dec 2017
- Locations
- 1 site, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide